

NAG6 siRNA (h): sc-89356

BACKGROUND

NAG6 (nasopharyngeal carcinoma-associated gene 6 protein), also known as CCDC136 (coiled-coil domain-containing protein 136), is a 1,154 amino acid single-pass membrane protein that exists as four alternatively spliced isoforms. Expressed in gastric tissue, NAG6 is downregulated in gastric cancers and is encoded by a gene that maps to human chromosome 7q32.1. Chromosome 7 houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 has been linked to osteogenesis imperfecta, Pendred syndrome, lissencephaly, citrullinemia and Shwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 is associated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, an unusual comfort and friendliness with strangers and an elfin appearance. Deletions of portions of the q arm of chromosome 7 are also seen in a number of myeloid disorders including cases of acute myelogenous leukemia and myelodysplasia.

REFERENCES

1. Tsipouras, P., et al. 1983. Restriction fragment length polymorphism associated with the proc α 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. *J. Clin. Invest.* 72: 1262-1267.
2. Liang, H., et al. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. *Proc. Natl. Acad. Sci. USA* 95: 3781-3785.
3. Jiang, N., et al. 2000. A cDNA located on chromosome 7q32 shows loss of expression in epithelial cell line of nasopharyngeal carcinoma. *Chin. Med. J.* 113: 650-653.
4. Iwasaki, S., et al. 2001. Long-term audiological feature in Pendred syndrome caused by PDS mutation. *Arch. Otolaryngol. Head Neck Surg.* 127: 705-708.
5. Zhang, X.M., et al. 2004. Expression of tumor related gene NAG6 in gastric cancer and restriction fragment length polymorphism analysis. *World J. Gastroenterol.* 10: 1361-1364.
6. Osborne, L.R., et al. 2006. Williams-Beuren syndrome diagnosis using fluorescence *in situ* hybridization. *Methods Mol. Med.* 126: 113-128.
7. Reiner, O., et al. 2006. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. *Neuromolecular Med.* 8: 547-565.
8. Gilbert-Dussardier, B. 2006. Williams-Beuren syndrome. *Rev. Prat.* 56: 2102-2106.
9. Leone, G., et al. 2007. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. *Haematologica* 92: 1389-1398.

CHROMOSOMAL LOCATION

Genetic locus: CCDC136 (human) mapping to 7q32.1.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

NAG6 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see NAG6 shRNA Plasmid (h): sc-89356-SH and NAG6 shRNA (h) Lentiviral Particles: sc-89356-V as alternate gene silencing products.

For independent verification of NAG6 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-89356A, sc-89356B and sc-89356C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

NAG6 siRNA (h) is recommended for the inhibition of NAG6 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor NAG6 gene expression knockdown using RT-PCR Primer: NAG6 (h)-PR: sc-89356-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.